Zobrazeno 1 - 7
of 7
pro vyhledávání: '"James H. Stoltz"'
Autor:
Kerry T. Blanchard, Sylvia M. Furst, John H. Mennear, James H. Stoltz, J. B. Majeska, P. D. Lilly, R. E. Stoll
Publikováno v:
Toxicological Sciences. 90:440-450
Phenolphthalein (800 and 2400 mg/kg/day by gavage and 2400 mg/kg/day by diet) and bisacodyl (800-500, 4000-2000, and 8000 mg/kg/day by gavage) were administered to 15 male and 15 female and 20 male and 20 female p53(+/-) mice respectively for 26 week
Autor:
Supriya Jayadev, Qihong Huang, Kerry T. Blanchard, Franklin D. Pack, Elias T. Gaillard, James H. Stoltz, Brian Knight, Xidong Jin
Publikováno v:
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 549:147-167
Microarray technology continues to gain increased acceptance in the drug development process, particularly at the stage of toxicology and safety assessment. In the current study, microarrays were used to investigate gene expression changes associated
Autor:
Lynn Pantages, George Kukolj, Brian Knight, Mireille Cartier, Louiza Mahrouche, Martine Brault, Tim T. Chiu, Louise Pilote, Peter W. White, Michael G. Cordingley, Nathalie Uyttersprot, Frédéric H. Vaillancourt, Richard Bethell, Anne-Marie Faucher, James H. Stoltz, Steffen Breitfelder, Elias T. Gaillard, Mary McFarland, Huiping Jiang
Publikováno v:
Journal of Virology
Phosphatidylinositol-4-kinase IIIα (PI4KIIIα) is an essential host cell factor for hepatitis C virus (HCV) replication. An N-terminally truncated 130-kDa form was used to reconstitute an in vitro biochemical lipid kinase assay that was optimized fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb796c8b8a6dc63ee044eee1c9692ef5
https://europepmc.org/articles/PMC3486294/
https://europepmc.org/articles/PMC3486294/
Autor:
Daniel Potenta, Arthur Roth, Lewis B. Kinter, Carl L. Alden, Thomas Singer, Charles R. Mahrt, Joseph J. DeGeorge, Andrew R. Kraynak, John Evans, Bruce A. Trela, Richard Perry, Ronny Fransson-Steen, Jochen Woicke, Rabih Slim, Susan E. Turnquist, Matt Liu, David Brewster, Sandra De Jonghe, Karyn Colman, Douglas A. Keller, Vanessa Bosmans, Oliver C. Turner, Mark A. Dominick, Sivert Bjurström, M. Vijayaraj Reddy, James R. Hailey, Richard D. Storer, Frank D. Sistare, James R. Myer, Marjolein van Heerden, Keith A. Soper, Philip Sherratt, Daniel Morton, James H. Stoltz, Joel Christensen, Dirk Mariën, Jean-Guy Bienvenu
Publikováno v:
Toxicologic pathology. 39(4)
Data collected from 182 marketed and nonmarketed pharmaceuticals demonstrate that there is little value gained in conducting a rat two-year carcinogenicity study for compounds that lack: (1) histopathologic risk factors for rat neoplasia in chronic t
Autor:
Randolph Seidler, Qihong Huang, Brian Knight, James H. Stoltz, Jerry O. Stern, Franklin D. Pack
Publikováno v:
Toxicologic pathology. 39(3)
BILN 2061 is a potent, reversible inhibitor of hepatitis C virus NS3/NS4A serine protease. Early clinical proof of principle with the drug was offset by the results of subsequent safety studies in Rhesus monkeys revealing cardiotoxicity that featured
Publikováno v:
Toxicologic pathology. 29(5)
The Tg.AC mouse is being evaluated for use in short-term carcinogenicity bioassays. Because the dermal test protocol necessitates dissolving test agents we determined the effects of several solvents on responsivenes s of hemizygous mice to dermal app
Autor:
Sylvia M. Furst, James H. Stoltz, Kerry T. Blanchard, Raymond E. Stoll, Henry E. Holden, D. J. Ball
Publikováno v:
Toxicologic pathology. 26(4)
Assessment of the carcinogenic potential of chemical agents continues to rely primarily upon the chronic rodent bioassay, a resource-intensive exercise. Recent advances in transgenic technology offer a potential resource conserving approach to carcin